NX Development Corp Submits Supplemental New Drug Application to FDA for MEN-301 Study
-
Mehbooba Mufti urges dialogue and renewed Central Asia links for Kashmir
-
Bezos grant helps Seattle nonprofit move thousands of families toward housing
-
Seacliff Healthcare Seeks Specialist GP in Thirroul
-
Shrini Srivastava joins crew of Varanasi-Delhi Vande Bharat Sleeper service
-
US stocks fall before midterm Election Day as technology shares weaken
-
Nearly Half of Australian Workers Overqualified, Survey Finds
-
BLS Polymers makes strong market debut at ₹248 per share
-
RBI eases export-declaration compliance for individual service exporters
-
Petrol and diesel prices remain broadly steady across major Indian cities
-
India proposes more import entry points for drugs and medical devices
-
Reliance shares remain in focus after near-12% surge
-
Derek Tierney Outlines Ten-Year Strategy for National Digital Health System
-
2026 Arizona Midterms: Key Races, Ballot Measures, and Voter Deadlines
-
NBC’s Steve Kornacki Reveals Tech Habits Ahead of Midterm Elections
-
Coal India prepares possible $1 billion Mahanadi Coalfields listing
-
India and Israel oppose UN draft on regional conventional arms control
-
Julia Stiles and Ezra Sosa Share Emotional Farewell After 'DWTS' Elimination
-
BLS Polymers shares open 65.3% above IPO price
-
US Buildings Threatened by Wildfires Could Triple by 2060
-
Capital-markets shares rally as Motilal Oswal and Angel One lead gains
-
Why Pregnancy Cost Estimates Fail: A Family’s $9,000 Surprise
-
Latino Voters Defy ICE Fears, Turn Out in Record Numbers for Midterms
-
US Strikes Iranian Targets in Strait of Hormuz Ahead of Midterms
-
ITC shares rise as analysts anticipate gradual cigarette-business recovery
-
Brodeur’s Overtime Goal Secures Bethlehem’s Second Consecutive Sectional Title
-
Reliance rally puts historical one-year return pattern in focus
-
Rare 1970 Plymouth ‘Cuda 426 Hemi Listed for $400,000
-
Kuwait edges Oman 1-0 in veterans Gulf Cup in Doha
-
The Digital Burden: Why Instant Messaging Feels Like a Full-Time Job
-
Saudi Aramco quarterly profit climbs 34.6% amid elevated oil prices
-
Alberta Tabled Controversial Riding Boundary Maps Amid Gerrymandering Accusations
-
Washington reports movement in Iran negotiations aimed at preventing escalation
-
Hong Kong court set to sentence activist Joshua Wong in security case
-
Korea’s Labor Share of GDP Hits Record Low Amid Semiconductor Boom
-
Australia raises benchmark rate to highest level in 18 years
-
littlefish and Halo Dot Partner to Replace Payment Terminals with SoftPOS
-
'The Remarried Empress' Cast Discusses Bringing Fantasy Royal Drama to Life
-
Kuwait inspectors destroy 115 kilograms of unverified meat in Farwaniya
-
Asian stocks retreat as AI worries outweigh steep oil-price drop
-
Egypt Accelerates Construction of 341km Sinai Railway Linking Arish and Taba
-
Hamad International Airport stages emergency drills during WATAN 2026
-
John Schneider Admits Owes Millions in 'Dukes of Hazzard' Divorce Battle
-
Global failure to punish attacks leaves journalists at continuing risk
-
Philippine Authorities Report Progress in Thomas Markle Sr. Child Pornography Probe
-
Researchers Warn 'Bookkeeping Trick' Masks Beef Industry's Methane Emissions
-
Web Summit Qatar 2026 generated QR1 billion economic impact, report says
-
Climate Change Intensified Atlantic Hurricanes, Study Finds
-
UAE oil spill raises questions for desalination operations
-
Qatar solar expansion opens scope for technical performance gains
-
Doha hotel and Carolina Herrera launch fragrance-inspired afternoon tea
NX Development Corp Submits Supplemental New Drug Application to FDA for MEN-301 Study
LEXINGTON, KY / ACCESS Newswire / April 6, 2026 / NX Development Corp (NXDC) is pleased to announce that after successfully completing the data analysis of our MEN-301 Study of the use of Gleolan® (aminolevulinic acid HCl) to enhance visualization of newly diagnosed or recurrent meningioma, we have submitted these data to the FDA for review as part of an efficacy supplement to our Gleolan New Drug Application (NDA).
"This marks the first submission of supplemental data to the FDA since our original approval for high-grade glioma in 2017, and the culmination of a great amount of hard work by our dedicated NXDC team in advancing the science of fluorescence-guided surgery," said Salvatore DeSena, MD, CEO of NX Development Corp. "Without doubt we are pleased with these results, and we look forward to the FDA review process."
"This submission to the FDA is another important milestone not only for NXDC but also for our whole group," added Dr. Ulrich Kosciessa, Chairman of the Board of NXDC and CEO of photonamic GmbH & Co. KG. "We are dedicating our full attention to provide solutions for unmet medical needs using 5-Aminolevulinic Acid (5-ALA) in the field of fluorescence-guided surgery for patients and healthcare professionals globally."
About NX Development Corp. (NXDC)
NXDC is a privately held life science company dedicated to the commercialization of Gleolan in the U.S. The company was acquired in 2018 by photonamic (PHN) GmbH & Co. KG. (Pinneberg, Germany). PHN is wholly owned by SBI ALApharma GmbH (Germany), a subsidiary of SBI Holdings, Inc. (Tokyo, Japan).
About Gleolan® (aminolevulinic acid HCl)
Gleolan is an FDA-approved optical imaging agent indicated in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery. Gleolan helps neurosurgeons see malignant tissue in real time during surgery and is provided orally (20mg/kg), 2-4 hours prior to glioma surgery. During the operation, the surgeon utilizes a surgical microscope with a specific blue light filter for the visualization of red-violet fluorescence.
Please see Full Prescribing Information.
Contact: Phone: 833-471-3282 | Email: [email protected]
SOURCE: NX Development Corp
View the original press release on ACCESS Newswire
P.Costa--AMWN